---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-113893"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:55:55.834278+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProKidney reports 2025 net loss $151.6M, cash $270M; Phase 3 PROACT 1 on track for mid-2026 enrollment

## Summary
- Net loss $151.6M in 2025 vs $163.3M in 2024; no revenue as pre-revenue cell therapy company.
- Cash and marketable securities $270.0M at Dec 31, 2025, down from $358.3M; runway into mid-2027.
- Phase 3 PROACT 1 enrollment for accelerated approval (n~360) on track for mid-2026; top-line eGFR slope data Q2 2027.
- FDA confirmed in July 2025 Type B meeting that eGFR slope can serve as surrogate endpoint for accelerated approval.
- Positive Phase 2 REGEN-007 results presented at ASN Kidney Week 2025 and published in CJASN.

## SEC filing metadata
- accession: 0001193125-26-113893
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000119312526113893/0001193125-26-113893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000119312526113893/prok-20260318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-113893
- JSON: https://secwatch.observer/filing/0001193125-26-113893.json
- Plain text: https://secwatch.observer/filing/0001193125-26-113893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.